Triesence (triamcinolone acetonide injectable suspension)
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
320
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
June 10, 2025
Intraocular Inflammation Following Faricimab Intravitreal Injection Treated With Sub-tenon Triamcinolone Acetonide Injection.
(PubMed, Cureus)
- "In this study, IOI was managed with a STTA injection during the early stage of uveitis. Severe inflammation can lead to complications such as posterior iris synechia."
Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis
June 12, 2025
Predictive value of short-term steroid intraocular pressure elevation testing for long-term steroid intraocular pressure elevation in diabetic macular edema treatment.
(PubMed, Int Ophthalmol)
- "It is crucial to evaluate the necessity of a prior short-acting steroid challenge, which carries the risk of multiple disease relapses, given the potential for a prolonged and stable steroid to provide superior control. The predictive value of the test with TA was not evident in our sample, suggesting some usefulness in delaying treatment with the FAc implant."
Journal • Observational data • Retrospective data • Diabetic Macular Edema • Ophthalmology
June 12, 2025
Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema.
(PubMed, Jpn J Ophthalmol)
- "IOI developed in four of 56 (7.1%) eyes and responded well to prompt steroid therapy after 1.5 years of IVBr use for DME. BCVA and CMT improved at all evaluation time points. With an average of 3.8 IVBr injections per year, IVBr showed long-term efficacy for DME in the real-world setting, although the occurrence of IOI should be monitored."
Journal • Real-world evidence • Diabetic Macular Edema • Inflammation • Ocular Inflammation • Ophthalmology
June 08, 2025
Revisiting the Role of Intravitreal Triamcinolone in Diabetic Macular Edema: 12-Month Outcomes after Bevacizumab Failure.
(PubMed, Ophthalmol Ther)
- "Repeated IVTA treatments for DME refractory to bevacizumab over a 12-month period demonstrated efficacy and appeared to have a comparable safety profile. Patients with thinner CMT before IVTA treatment had a greater probability of remaining DME-free after IVTA treatment."
Journal • Diabetic Macular Edema • Ophthalmology
June 06, 2025
Treatment of Non-Infectious Uveitis Macular Edema Using Two Doses of Triamcinolone Acetonide: Comparative Study.
(PubMed, Ocul Immunol Inflamm)
- "Although an IOP spike occurred in both groups 1 week post-procedure, no intraocular hypertension was observed 90 days post-procedure. Visual acuity outcomes were comparable between both groups at the end of the follow-up."
Journal • Cardiovascular • Cataract • Glaucoma • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis
May 04, 2025
Beyond the injection: delivery systems reshaping retinal disease management.
(PubMed, Expert Opin Pharmacother)
- "Specific innovations discussed include the ranibizumab port delivery system, EYP-1901 (Duravyu, vorolanib implant), KSI-301 (tarcocimab tedromer), KSI-501, OTX-TKI (Axpaxli, axitinib implant), 4D-150, revakinagene taroretcel-lwey (Encelto, NT-501, encapsulated cell therapy), Xipere (triamcinolone acetonide injectable suspension), AU-011 (belzupacap sarotalocan targeted delivery), ABBV-RGX-314, elamipretide, and OCS-01 (high concentration dexamethasone)...Challenges include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence. Advances in smart delivery systems, drug formulations, and predictive models, alongside interdisciplinary collaboration, will be crucial in achieving personalized, effective, and sustainable retinal therapies."
Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders
May 19, 2025
Changes of diabetic macular edema post vitrectomy in patients with proliferative diabetic retinopathy.
(PubMed, Int J Ophthalmol)
- "PV-DME is a very common postoperative complication in patients with PDR. Triamcinolone acetonide could prevent its formation. Attention should be paid to patients with a thicker preoperative CRT and internal limiting membrane peeling."
Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders
May 09, 2025
Novel in vitro model for intravitreal drug dissolution and release studies of small molecules and their long-acting formulations.
(PubMed, J Control Release)
- "Furthermore, we demonstrated suitability of the model for long-acting formulations in a 150-day experiment with triamcinolone acetonide suspension. The suspension displayed similar elimination trend as has been observed in rabbits. We believe this system can lead the way in introducing site-specific drug release testing for the intravitreal route."
Journal • Preclinical • Ophthalmology
April 21, 2025
Intravitreal low-dose triamcinolone acetonide for nonarteritic anterior ischemic optic neuropathy.
(PubMed, Int J Ophthalmol)
- "Low-dose IVTA may be an alternative safe treatment option for some NAION patients in the acute stage. However, optic nerve atrophy still existed."
Journal • Cardiovascular • Diabetic Retinopathy • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders
April 11, 2025
Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis.
(PubMed, JAMA Ophthalmol)
- "Five randomized clinical trials were preselected for analysis, including the RIDE and RISE trials (Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus); Protocol I (Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema), Protocol S (Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy), and Protocol T (A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema)...No difference in BCVA was observed in Black vs White participants at 2 years. Smaller enrollment numbers precluded analysis of participants of other races, suggesting lack of robust diversity beyond Black and White participants in these trials."
Clinical • Journal • Retrospective data • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders
April 04, 2025
Occlusive Retinal Vasculitis After Aflibercept 8mg Injection for Wet Macular Degeneration.
(PubMed, Retin Cases Brief Rep)
- "ORV is a rare complication of some intravitreal anti-VEGF medications and infectious causes of endophthalmitis. It can be managed with aggressive steroid treatment for an excellent visual outcome in some cases, although the disease may be chronic or recurrent."
Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration
March 26, 2025
Human Umbilical Cord-Derived Mesenchymal Stem Cells via Suprachoroidal Injection: A Novel Approach for Experimental Uveitis Treatment
(ARVO 2025)
- "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Ocular Inflammation • Ophthalmology • Uveitis • IL17A • TNFA
March 28, 2025
Incidence, Pathogenesis, Risk Factors, and Treatment of Cystoid Macula Oedema Following Cataract Surgery: A Systematic Review.
(PubMed, Diagnostics (Basel))
- "Studies evaluating topical NSAIDs, periocular steroids, intravitreal triamcinolone acetonide (TCA), dexamethasone implants (Ozurdex), and intravitreal bevacizumab were included... Topical NSAIDs, particularly ketorolac and diclofenac, showed effectiveness in acute CMO, while their efficacy in chronic cases was variable... Topical NSAIDs, often combined with periocular steroids, serve as first-line therapy, with periocular steroids offering additional efficacy in resistant cases. Further research is needed to establish optimal treatment algorithms and improve outcomes for patients with post-operative CMO."
Journal • Review • Cataract • Macular Edema • Ophthalmology
March 26, 2025
Dropless vitrectomy surgery for epiretinal membranes; Efficacy and safety compared to standard of care
(ARVO 2025)
- "Methods A retrospective review was conducted on patients who underwent PPV for ERM removal.Group 1 received an intravitreal injection of Tri-Moxi (0.3mL, delivering 4.5mg triamcinolone acetonide & 0.3mg moxifloxacin) at the conclusion of surgery.Group 2 received a standard postoperative regimen of Tobradex eye drops every 4 hours for 1 week, tapered over 5 additional weeks(6 weeks total)...This method facilitates the direct delivery of concentrated anti-inflammatory and antibacterial agents to the retina and vitreous cavity, where these effects are most beneficial after PPV. In our study, we demonstrated that administering a low dose of intravitreal triamcinolone acetonide directly into the vitreous effectively achieves therapeutic levels for managing postoperative inflammation following PPV for ERM removal."
Clinical • Surgery • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders
March 25, 2025
Risk of intraocular pressure elevation associated with triamcinolone acetonide administration via different routes in macular edema: a systematic review and network meta-analysis of randomized controlled trials.
(PubMed, BMC Ophthalmol)
- "For the increased risk of IOP, we recommend that treatment within 4 weeks is safe. Nevertheless, it is advisable to exercise caution when administering IVTA, STiTA, SCTA beyond a duration of 12 weeks, due to the potential risk of IOP elevation. RITA emerged as the safest injection route in the treatment of macular edema in terms of IOP risk. However, more high-quality randomized controlled trials will be necessary to further confirm this."
Clinical • Journal • Retrospective data • Review • Macular Edema • Ophthalmology
March 26, 2025
Adverse Events Associated with Injection of Suprachoroidal Triamcinolone Acetonide in the Real-World Setting
(ARVO 2025)
- "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Adverse events • Clinical • Real-world • Real-world evidence • Cataract • Glaucoma • Macular Edema • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis
March 26, 2025
A case of retinal phlebitis complicated by punctate inner choroidopathy-like lesion
(ARVO 2025)
- "The patient was started on oral prednisolone (PSL) therapy...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Clinical • Ocular Inflammation • Ophthalmology
March 27, 2025
Dynamics of Inflammatory Factors in Aqueous Humor During Brolucizumab Treatment for Age-Related Macular Degenerations: A Case Series.
(PubMed, Medicina (Kaunas))
- "Vision worsened in one patient who developed IOI after initial IVBr, so IVBr was discontinued and the patient was switched to intravitreal aflibercept with sub-tenon injection of triamcinolone acetonide...In two patients with IOI, not only flares but also IL-8, IP-10, and Flt-3L decreased from 1 to 2 months after IVBr despite continued IVBr. This case series might lead to a better understanding of the pathogenesis of IOI after IVBr."
Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CCL2 • CX3CL1 • CXCL8 • FLT3 • FLT3LG • IL6
March 20, 2025
Efficacy and Safety of Ophthalmic Steroids in the Management of Polypoidal Choroidal Vasculopathy: A Systematic Review.
(PubMed, Clin Ophthalmol)
- "Triamcinolone acetonide was administered in seven studies, and dexamethasone in two...The maximum reduction observed in the central foveal thickness and central retinal thickness was -131.4 μm and -261.7 μm, respectively. Ophthalmic steroids may serve as an effective adjunctive treatment for PCV patients, irrespective of anti-VEGF resistance or hemorrhagic involvement, and may be considered as a potential monotherapy in resource-limited settings, with minimal side effects."
Journal • Review • Age-related Macular Degeneration • Cardiovascular • Cataract • Glaucoma • Hematological Disorders • Ophthalmology • Retinal Disorders
March 18, 2025
From Monotherapy to Combination Strategies: Redefining Treatment Approaches for Multiple-Cause Macular Edema.
(PubMed, Clin Ophthalmol)
- "Combination therapies, including anti-VEGF drugs with macular laser photocoagulation, triamcinolone acetonide, or dexamethasone intravitreal implant (Ozurdex), have emerged as promising strategies...Future research directions are outlined, emphasizing the importance of large-scale, long-term studies to evaluate the sustained efficacy and safety of combination therapies. The integration of advanced imaging techniques, biomarker analysis, and innovative therapeutic approaches is expected to shape the future landscape of ME management, moving towards more targeted and effective combination therapies."
Journal • Monotherapy • Review • Diabetic Macular Edema • Inflammation • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion
March 17, 2025
Potential association of bilateral macular edema with retinal vein occlusion triggered by volatile organic compounds of paint: A case report.
(PubMed, Am J Ophthalmol Case Rep)
- "He was treated with triamcinolone acetonide and anti-VEGF intravitreal injections, and later with vitrectomy combined with cataract surgery in both eyes due to a persistent bilateral CME...A CME might be exacerbated by the exposure to paint-related VOCs. Our findings suggest that reducing and avoiding the occupational exposure to VOCs and regular measurements of urinary VOC concentration are important for those who work in the printing and painting industries."
Journal • Cataract • Macular Edema • Ophthalmology • Retinal Vein Occlusion
March 14, 2025
Recurrent uveitic macular edema managed with intravitreal faricimab injection.
(PubMed, J Ophthalmic Inflamm Infect)
- "The findings of this case hint towards the potential simultaneous effect of angiopoietin-2 blockade along with vascular endothelia growth factor A inhibition by faricimab in managing treatment-resistant UME. Nonetheless, more studies focusing on the role of intravitreal faricimab in UME are required."
Journal • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Vasculitis
March 11, 2025
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE
(Businesswire)
- "Harrow...announced the execution of a five-year strategic supply and development ('SSD') agreement for TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. The SSD agreement is with the current contract manufacturing organization (CMO) producing TRIESENCE, ensuring continuity in quality and leveraging more than 15 years of experience with the TRIESENCE manufacturing process. Harrow also announced that it has begun developing a next-generation version of TRIESENCE and plans to submit a new drug application (NDA) to the FDA before the end of 2027."
Commercial • FDA filing • Ocular Inflammation
February 26, 2025
Epstein-Barr Virus Associated Frosted Branch Angiitis.
(PubMed, Retin Cases Brief Rep)
- "Bilateral FBA may present following EBV infection and responds well to corticosteroids and antiviral therapy."
Journal • CNS Disorders • Epstein-Barr Virus Infections • Genetic Disorders • Infectious Disease • Inflammation • Ocular Inflammation • Pain • Retinal Disorders • Vasculitis
February 17, 2025
Bilateral Foveal Damage Induced by Indirect Picosecond Nd:YAG Laser Exposure: A Case Report.
(PubMed, Case Rep Ophthalmol Med)
- "Injections of sub-Tenon's triamcinolone acetonide (12 mg/0.3 mL) in the right eye and intravitreal tissue plasminogen activator (30 μg/0.05 mL) in the left eye were administered on the same day... Continuous Nd:YAG laser exposure during cosmetic procedures likely caused the bilateral foveal damage observed in this case. All individuals using lasers must be aware of the importance of protective goggles."
Journal • Aesthetic Medicine • Hematological Disorders • Ophthalmology • Retinal Disorders
1 to 25
Of
320
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13